摘要
目的观察0.5%氯替泼诺滴眼液治疗中重度干眼病的临床疗效。方法按标准纳入中重度干眼患者40例,回顾性分两组:联合用药组予0.5%氯替泼诺滴眼液和新泪然滴眼液联合用药;单用药组用新泪然滴眼液。在治疗前及治疗后2、4、6周观察眼表疾病指数(OSDI)、泪膜破裂时间(BUT)、泪液分泌实验(Schirmer I试验)、眼表染色评分(OSS评分)、眼压;ELISA测泪液中炎症介质白介素-6(IL-6)的表达。结果治疗2周后,联合用药组OSDI评分均值明显降低,较治疗前差异有显著性(P<0.05);治疗2周联合用药组眼表炎症体征减轻;联合用药组BUT均较治疗前延长;两组各时间点的Sehirmer I及眼压值无明显变化。结论 0.5%氯替泼诺滴眼液通过下降IL-6表达,减轻中重度干眼眼表炎症,安全有效。
Objective To observe the effect of 0.5% loteprednol eye drops on the clinical efficacy of moderate-se- vere dry eye and investigate the potential mechanism of loteprednol eye drops in anti-inflammation. Method 40 cases of moderate-severe dry eye patients according to the clinical standards were randomly divided into two groups：Experimental group （0.5% loteprednol eye drops together with Hypromellose 2910 eye drops）;The control （Hypromellose 2910 eye drops ）. After treatment of loteprednol eye drops for 2,4,6weeks, and ocular Surface Disease Index （OSDI） , tear film break- up time（BUT） ,Schirmer test I（ Schirmer I test）, ocular surface staining（OSS） score and intraocular pressure were ob- served, the IL-6 expression in the tear fluid was detected by Enzyme-linked immunosorbent assay （ELISA）. Result Af- ter two weeks of treatment＇, the OSDI mean score of experimental group was significantly reduced, the difference was statisti- cally significant （ P 〈 O. 05 ） than before treatment, and ocular inflammation signs of experimental group was alleviated ; BUT of Experimental group was extended than before treatment ; Sehirmer I and NCT in two groups at each time point were not significantly changed. Conclusions 0.5% loteprednol eye drops could decrease the expression of IL-6 and relieve the symptom of moderate to severe dry eye ocular inflammation;so it is safe and effective.
出处
《中南医学科学杂志》
CAS
2013年第5期486-489,共4页
Medical Science Journal of Central South China
关键词
干眼
氯替泼诺
炎症介质
dry eye
loteprednol
inflammatory mediators
